GlaxoSmithKline (GSK) has announced FDA approval of raxibacumab anti-toxin as a combination therapy along with antibacterial drugs for the treatment of inhalational anthrax in both adult and pediatric patients with limited treatment ...
The Anti-Infective Drugs Advisory Committee to the US Food and Drug Administration (FDA) has supported the clinical benefit of GlaxoSmithKline's raxibacumab to treat inhalational anthrax. In addition, the committee also favoured the ...
Tags: The Anti-Infective Drugs, raxibacumab anti-toxin development programme